41 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
RGNX REGENXBIO Inc. $70.3974 $2.27B N/A
Article Searches
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio https://www.fool.com/investing/2019/05/24/approval-of-a-game-changing-gene-therapy-for-sma-d.aspx?source=iedfolrf0000001 May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4261299-regenxbio-inc-rgnx-ceo-kenneth-mills-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 07, 2019 - Regenxbio, Inc. (NASDAQ:RGNX) Q1 2019 Earnings Conference Call May 07, 2019, 16:30 ET Company Participants Patrick Christmas - SVP & General Counsel Kenneth Mills - CEO, President & Director S
Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/07/regenxbio-inc-rgnx-q1-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001 May 07, 2019 - RGNX earnings call for the period ending March 31, 2019.
Top Gene-Sequencing Stocks for 2019 https://www.fool.com/investing/2019/04/19/top-gene-sequencing-stocks-for-2019.aspx?source=iedfolrf0000001 Apr 19, 2019 - These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019 http://www.zacks.com/stock/news/372303/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019?cid=CS-ZC-FT-372303 Apr 08, 2019 - Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
3 Small-Cap Biotech Stocks to Watch Now https://www.fool.com/investing/2019/04/03/3-small-cap-biotech-stocks-to-watch-now.aspx?source=iedfolrf0000001 Apr 03, 2019 - These under-the-radar stocks could be poised to make big moves in the coming months.
DOC, NBR, HABT and RGNX among notable after hour movers https://seekingalpha.com/news/3445220-doc-nbr-habt-rgnx-among-notable-hour-movers?source=feed_news_all Mar 22, 2019 - Top Gainers: DOC +4.8%. SENS +4.7%. RMTI +3.4%. UXIN +2.4%. NBR +2.3%.Top Losers: HABT -2.8%. RGNX -2.7%. CPLG -1.9%. SONO -1.5%. HEAR -1.1%.
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next? https://www.fool.com/investing/2019/03/08/gene-therapy-ma-has-shares-skyrocketing-could-this.aspx?source=iedfolrf0000001 Mar 08, 2019 - Roche and Biogen are spending big bucks on gene therapy biotech stocks.
3 Top Small-Cap Stocks to Buy Right Now https://www.fool.com/investing/2019/03/04/3-top-small-cap-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 Mar 04, 2019 - These three small-cap stocks have outstanding growth potential.
REGENXBIO (RGNX) CEO Ken Mills on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4245035-regenxbio-rgnx-ceo-ken-mills-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 27, 2019 - REGENXBIO (NASDAQ:RGNX) Q4 2018 Results Earnings Conference Call February 27, 2019, 4:30 am ET Company Participants Patrick Christmas - Senior Vice President, General Counsel Ken Mills - President, Ch

Pages: 12345

Page 1>